Safety Profile of Psilocybin for Cocaine Use Disorder (opens ClinicalTrials.gov in a new tab)
Suspended Early Phase 1 10 participants University of California, Los Angeles
Cocaine Use Disorder
Suspended Early Phase 1 10 participants University of California, Los Angeles
Cocaine Use Disorder
Suspended Early Phase 1 5 participants University of Wisconsin, Madison
Posttraumatic Stress Disorder
Not yet recruiting Early Phase 1 20 participants Yale University
Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI
Not yet recruiting Early Phase 1 10 participants NYU Langone Health
IBS - Irritable Bowel Syndrome
Recruiting Early Phase 1 18 participants Johns Hopkins University
Psychedelic Effects in Healthy Volunteers
Not yet recruiting Early Phase 1 60 participants Roswell Park Cancer Institute
Cannabis Dependence
Not yet recruiting Early Phase 1 144 participants University of Illinois at Chicago
Cannabis Use, Substance Use Disorder (SUD), Healthy
Recruiting Early Phase 1 20 participants Spaulding Rehabilitation Hospital
Fibromyalgia
Not yet recruiting Early Phase 1 10 participants Yale University
Smokers With Chronic Pain
Recruiting Early Phase 1 10 participants University of Texas Southwestern Medical Center
Traumatic Brain Injury, Traumatic Encephalopathy
Recruiting Early Phase 1 12 participants University of Virginia
Prolonged Grief Disorder
Recruiting Early Phase 1 70 participants Northwestern University
Anxiety
Recruiting Early Phase 1 220 participants Min Su
Esketamine, ECT, Depression, Adolescent
Completed Early Phase 1 25 participants Northwestern University
Anxiety
Recruiting Early Phase 1 30 participants Imperial College London
Self Harm
Completed Early Phase 1 42 participants University of Chicago
LSD
Completed Early Phase 1 41 participants University of Chicago
LSD, Major Depressive Disorder, Depression
Recruiting Early Phase 1 50 participants Yale University
Migraine
Recruiting Early Phase 1 24 participants Johns Hopkins University
Amyotrophic Lateral Sclerosis
Recruiting Early Phase 1 20 participants Kevin Murnane
Methamphetamine Use Disorder
Not yet recruiting Early Phase 1 100 participants University of Zurich
Depressive Symptoms Mild to Moderate in Severity, Anxiety, Quality of Life (QOL), Caregiver Burden
Recruiting Early Phase 1 5 participants Second Affiliated Hospital, School of Medicine, Zhejiang University
Treatment-resistant Depression (TRD)
Enrolling by invitation Early Phase 1 150 participants AgelessRx
Longevity, Quality of Life, Mood, Inflammation
Active, not recruiting Early Phase 1 12 participants University of Washington
Narcissism
Active, not recruiting Early Phase 1 40 participants Rigshospitalet, Denmark
Basic Science
Data from ClinicalTrials.gov, refreshed daily for the topics this library covers.